256) to consider when testing this transgenic model in the IntelliCage. |
257) should be included to more realistically model in vitro drug treatment. |
258) in vitro and in a streptozotocin diabetes model in vivo, metformin at diabetes-thera |
259) Overall, we propose a model in which TGF-β1 activates Rho/MRTF- |
260) Contrary to a previous model in which the formation of new corona |
261) e wild-type and trisomic mice (the Ts65Dn model) in one of the most used tests for p |
262) direct, and total effects for a mediation model with a categorical exposure and a ce |
263) The multilevel model with a decaying correlation structur |
264) Using a knock-in transgenic mouse model with a mutation in Gαo that does no |
265) We generated a transgenic murine model with conditional expression of the h |
266) We recommend a regulatory model with four signature features: (i) su |
267) We established a tauopathy mouse model with heterozygous knock-in of the hu |
268) d a tree-based multi-class classification model with physiological markers of heart |
269) the factorial structure of the ICD-11 PD model with respect to the anankastia domai |
270) alyzing blood PK profiles alone, the PBPK model with target binding yielded practica |
271) immune cell infiltration, we used a mouse model with varying methods of EFT applicat |
272) nol treatment in an early postnatal mouse model, with meaningful implications for ti |
273) By corollary, the de facto Rayleigh-Rice model, which assumes a rich multipath envi |
274) n of a representative human in vitro skin model, which can be used as an alternative |
275) d with the Larvae&Co larval dispersal model, which combines local hydrodynamics |
276) uccessfully constructed the CYP1A2 KO rat model, which provides a useful tool for st |
277) ed a thematic grid called the dimensional model, which qualitatively and quantitativ |
278) itutive androstane receptor, and CYP3A4/7 model, which was able to recapitulate the |
279) potential for further development of this model as a physiologically relevant gut in |
280) rscore the utility of the C3HeB/FeJ mouse model as a preclinical tool for evaluating |
281) ementation of a child mentalization-based model as a preventative intervention may c |
282) ominant disorder, is particularly hard to model as it manifests very differently acr |
283) a result, adjust the training dataset and model as needed. |
284) Model performance varied considerably with |
285) Model performance was assessed against bas |
286) how that the proposed method improves the model performance on AD diagnosis and achi |
287) how that the proposed method improves the model performance on AD diagnosis by 8.33% |
288) n-episode variability on machine learning model's performance for brushing surface d |
|